A Study of Oral Valcyte (Valganciclovir) in Pediatric Kidney Transplant Recipients

Completed · Phase 4

Conditions studied: Kidney Transplantation, Cytomegalovirus Infections

In brief

This open-label, single arm study will evaluate the tolerability and efficacy of Valcyte (valganciclovir) in the prevention of cytomegalovirus disease in pediatric renal transplant recipients. After transplantation, patients (aged 4 months to 16 years) will receive Valcyte orally daily for up to 200 days post-transplant and will be followed for 52 weeks post-transplantation.

Key facts

Study ID
NCT01376804
Run by
Hoffmann-La Roche
People needed
57
Starts
2011-07-31
Expected to finish
2013-05-31
Last updated by the study team
2017-07-11

Who can join

Age: 0 and older, up to 16. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.